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Summary
Background Few data are available from randomised trials about the eﬀ ect of thrombolysis with alteplase on long-term 
functional outcome in patients who have had acute ischaemic stroke and no trial has reported eﬀ ects on health-related 
quality of life. A secondary objective of the third International Stroke Trial (IST-3) was to assess the eﬀ ect of 
thrombolysis on such outcomes at 18 months.
Methods In this open-label, internation al, multicentre, randomised, controlled trial, 3035 patients with ischaemic 
stroke from 12 countries were randomly allocated within 6 h of onset via a secure central system to either intravenous 
alteplase (0·9 mg/kg; n=1515) plus standard care or standard care alone (control; n=1520). 2348 patients were 
scheduled for 18-month follow-up. For our main analysis, survivors were assessed at 18 months with the Oxford 
handicap scale (OHS; the primary outcome was the adjusted odds of OHS score 0–2). We also used the EuroQoL (EQ) 
instrument and asked questions about overall functioning and living circumstances. We analysed the OHS and the 
ﬁ ve EQ domains by ordinal logistic regression and calculated the mean diﬀ erence between treatment groups in EQ 
utility index and visual analogue scale score. Analyses were adjusted for key baseline prognostic factors. This study is 
registered with controlled-trials.com, number ISRCTN25765518.
Findings At 18 months, 408 (34·9%) of 1169 patients in the alteplase group versus 414 (35·1%) of 1179 in the control 
group had died (p=0·85). 391 (35·0%) of 1117 patients versus 352 (31·4%) of 1122 had an OHS score of 0–2 (adjusted 
odds ratio [OR] 1·28, 95% CI 1·03–1·57; p=0·024). Treatment was associated with a favourable shift in the distribution 
of OHS grades (adjusted common OR 1·30, 95% CI 1·10–1·55; p=0·002). Alteplase treatment was associated with 
signiﬁ cantly higher overall self-reported health (adjusted mean diﬀ erence in EQ utility index 0·060; p=0·019). The 
diﬀ erences between the groups in visual analogue scale score and the proportion living at home were not signiﬁ cant.
Interpretation IST-3 provides evidence that thrombolysis with intravenous alteplase for acute ischaemic stroke does 
not aﬀ ect survival, but does lead to statistically signiﬁ cant, clinically relevant improvements in functional outcome 
and health-related quality of life that are sustained for at least 18 months. 
Funding UK Medical Research Council, Health Foundation UK, Stroke Association UK, Research Council of Norway, 
AFA Insurances Sweden, Swedish Heart Lung Fund, The Foundation of Marianne and Marcus Wallenberg, Polish 
Ministry of Science and Education, the Australian Heart Foundation, Australian National Health and Medical 
Research Council, Swiss National Research Foundation, Swiss Heart Foundation, Assessorato alla Sanita (Regione 
dell’Umbria, Italy), and Danube University.
Introduction
Intravenous alteplase has been approved for treatment 
of acute ischaemic stroke in Europe for patients who 
are younger than 80 years and can be treated within 
4·5 h. Such use is associated with improved functional 
outcome at 3 months after stroke,1 but whether 
treatment improves survival and sustains functional 
recovery in the long term is unclear. Of the 12 completed 
randomised controlled trials, ten reported outcomes at 
90 days or less,1 two reported outcomes at 6 months,2,3 
and one reported outcomes at 12 months,3 but none 
have reported eﬀ ects at more than 1 year after stroke. 
Furthermore, the eﬀ ect of thrombolysis on health-
related quality of life—an important measure of the 
clinical and economic value of treatment—has not been 
reported to our knowledge. 
The third International Stroke Trial (IST-3)2 recruited 
3035 patients—half of whom were older than 80 years—
to assess the eﬀ ect of thrombolytic treatment with 
intravenous alteplase within 6 h of onset of acute 
ischaemic stroke. The results showed that although 
thrombolytic treatment was not associated with a 
signiﬁ cant diﬀ erence in the proportion of patients who 
were alive and independent at 6 months, treatment did 
seem to improve functional outcome. A prespeciﬁ ed 
secondary ordinal analysis of Oxford handicap scale 
scores showed that treatment was associated with a 
favourable shift in the distribution of Oxford handicap 
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scale scores (odds ratio [OR] 1·27, 95% CI 1·10–1·47; 
p=0·001).2 A secondary aim of IST-3 was to assess whether 
thrombolytic treatment improved outcomes more than 
1 year after stroke, and sought to assess survival, 
functional outcome, health-related quality of life, overall 
functioning, and living circumstances at 18 months.4,5 
Methods
Study design and participants
The methods of the trial have been described in full 
previously.2,4–6 IST-3 was a randomised, open-label trial of 
intravenous alteplase (0·9 mg/kg) plus standard care 
compared with standard care alone (control). Eligibility 
criteria were: symptoms and signs of clinically deﬁ nite 
acute stroke, known time of stroke onset, treatment could 
be started within 6 h of onset, and exclusion by CT or MRI 
of intracranial haemorrhage and structural brain lesions 
that could mimic stroke (eg, cerebral tumour). A patient 
could only be included in the trial if both they (or a proxy) 
and their clinician believed that the treatment was 
promising but unproven—ie, there was neither a clear 
indication for treatment, nor a clear contraindication 
against treatment. The eﬀ ect that using this uncertainty 
principle approach as a key eligibility criterion had on the 
type of patients included and excluded from the trial has 
been described in detail elsewhere.2,6 Generally, patients 
who could be treated within licence were rarely enrolled, 
unless there was a speciﬁ c reason that led the clinician or 
patient to be uncertain about whether to treat or not; as a 
result, 95% of enrolled patients did not meet the terms of 
the prevailing EU approval for treatment. All participants 
or proxies gave informed consent. The protocol was 
approved by the Multi-Centre Research Ethics Committee 
(Scotland) and by local ethics committees.
For the analysis presented here, we planned to assess 
outcome in patients who had follow-up at 6 months and 
18 months. In seven countries (Austria, Belgium, 
Canada, Italy, Mexico, Poland, and UK) follow-up had to 
cease on Jan 30, 2012; therefore, we excluded any patients 
from these countries who were recruited after June 30, 
2010, because they would not reach the 18-month 
follow-up point. In three countries (Australia, Norway, 
and Sweden), all recruited patients were to be followed 
up to 18 months, as part of a sub-study. Two countries 
(Portugal and Switzerland) followed up patients to 
6 months only and were not included in this analysis.
Randomisation
After enrolment, patients were randomly assigned by a 
secure central telephone or web-based computer system, 
which recorded baseline data and generated the 
treatment allocation only after the baseline data had been 
checked for range and consistency. The system used a 
minimisation algorithm to balance for key prognostic 
factors: geographic region, age, National Institutes of 
Health stroke scale score, sex, time since onset of stroke, 
stroke clinical syndrome, and presence or absence of 
visible ischaemic change on the pre-enrolment brain 
scan.4,5 To avoid predictable alternation of treatment 
allocation, and thus potential loss of allocation 
concealment, patients were allocated with a probability of 
0·80 to the treatment group that would minimise the 
diﬀ erence between the groups for the key prognostic 
factors. Recruitment in the small double-blind phase 
(n=276) began in May, 2000, continued without 
interruption into the open-treatment phase (n=2759), 
and was completed in July, 2011.
Procedures
In the ten countries participating in follow-up at 6 months 
and 18 months after enrolment (Australia, Austria, 
Belgium, Canada, Italy, Mexico, Norway, Poland, Sweden, 
and UK), if the patient was not known to have died, staﬀ  
at each national coordinating centre contacted the 
patient’s doctor (or hospital coordinator) to conﬁ rm that 
the patient was alive and that they might be approached 
for follow-up. In Austria and Italy, experienced stroke 
physicians, masked to treatment allocation, contacted all 
patients by telephone. In the other eight countries, 
IST-3 trial oﬃ  ce staﬀ  posted a questionnaire to patients to 
assess outcome. Non-responders were sent a second 
questionnaire. If no questionnaire was returned, an 
experienced, masked clinician or stroke nurse assessed 
the patient by telephone interview. Telephone assessment 
of disability in stroke survivors is as valid as face-to-face 
interviews7 and postal questionnaires.8
The primary outcome of the trial was the proportion of 
patients alive and independent with an Oxford handicap 
scale9 score of 0–2 at 6 months (this outcome was chosen 
Figure 1: Trial proﬁ le
EQ=EuroQoL. *Of the patients who were known to be alive at 18 months, 24 in the alteplase group versus 27 in 
the control group had a known date of death more than 18 months after enrolment, but their disability status at 
18 months was unknown. 
1515 allocated to alteplase 1520 allocated to control   
3035 participants enrolled
346 not followed up at 18 months 341 not followed up at 18 months
1169 follow-up at 18 months planned 1179 follow-up at 18 months planned 
854 alive 
778 included in analysis of EQ utility index
309 dead
     6 vital status and disability unknown 
859 alive
759 included in analysis of EQ utility index
310 dead 
   10 vital status and disability unknown 
733 alive*
674 included in analysis of EQ utility index
408 dead 
   28 vital status and disability unknown
735 alive* 
667 included in analysis of EQ utility index
414 dead
   30 vital status and disability unknown 
Outcome at 6 months
Outcome at 18 months
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instead of survival alone because many people regard 
survival after a stroke in a disabled or dependent state as 
worse than death). The secondary endpoints at 18 months 
were: survival, Oxford handicap scale score, health-related 
quality of life, overall functioning, and living 
circumstances. The Oxford handicap scale is a six-point 
scale almost identical to the modiﬁ ed Rankin scale.10 In 
emergency care of acute ischaemic stroke, recording 
quality of life at baseline before randomisation was not 
possible; instead, quality of life was measured at 6 months 
and 18 months with the EuroQoL instrument,11 which 
assesses current self-rated health by a combination of 
questions about wellbeing and a visual analogue scale 
score. The questions are about the ﬁ ve dimensions of 
mobility, self-care, activity, pain or discomfort, and anxiety 
(the EQ-5D). Each dimension has three levels (no 
problems, some problems, severe problems), which can 
be presented individually. A unique health state is deﬁ ned 
by combining one level from each of the ﬁ ve  dimensions. 
Patients’ responses can then be combined into an EQ 
utility index with scores ranging from –1 to +1 (where +1 
represents perfect health, 0 represents a state equivalent 
to death, and –1 represents a state worse than death). 
Calculation of the EQ utility index requires valuations for 
all health states, and these have been estimated for the 
UK and other European populations.12 For the visual 
analogue scale, 100 represents the best imaginable health 
and 0 the worst imaginable health. We used the EuroQoL 
instrument because it is short and simple, and in patients 
with stroke it has been validated,13–17 is responsive to 
change,18 and is associated with higher response rates and 
fewer missing data than more complex instruments.16 
Many patients who have had severe strokes might not be 
able to complete the questionnaire themselves and 
because responses from a proxy have reasonable 
validity,15,19 we therefore accepted responses submitted by 
a spouse, partner, close relative, or carer.
Alteplase group 
(n=1169)
Control group 
(n=1179)
Region
Americas (Canada, Mexico) 5 (<1%) 6 (1%)
Australia 89 (8%) 90 (8%)
Eastern Europe (Poland) 158 (14%) 159 (13%)
Northwest Europe (UK, Austria, 
Belgium)
550 (47%) 556 (47%)
Scandinavia (Norway, Sweden) 251 (21%) 250 (21%)
Southern Europe (Italy) 116 (10%) 118 (10%)
Age 
18–50 years 49 (4%) 57 (5%)
51–60 years 83 (7%) 81 (7%)
61–70 years 153 (13%) 158 (13%)
71–80 years 291 (25%) 304 (26%)
81–90 years 523 (45%) 512 (43%)
>90 years 70 (6%) 67 (6%)
Women 592 (51%) 596 (51%)
National Institutes of Health stroke scale score
0–5 235 (20%) 236 (20%)
6–10 323 (28%) 330 (28%)
11–15 244 (21%) 235 (20%)
16–20 207 (18%) 219 (19%)
>20 160 (14%) 159 (13%)
Delay in enrolment
≤3·0 h 320 (27%) 307 (26%)
>3·0–4·5 h 471 (40%) 481 (41%)
>4·5–6·0 h 378 (32%) 389 (33%)
>6·0 h 0 (0%) 2 (<1%)
Atrial ﬁ brillation 347 (30%) 331 (28%)
Systolic blood pressure
≤143 mm Hg 380 (33%) 380 (32%)
144–164 mm Hg 379 (32%) 405 (34%)
≥165 mm Hg 410 (35%) 394 (33%)
Diastolic blood pressure
≤74 mm Hg 342 (29%) 343 (29%)
75–89 mm Hg 409 (35%) 448 (38%)
≥90 mm Hg 406 (35%) 381 (32%)
(Continues in next column)
Alteplase group 
(n=1169)
Control group 
(n=1179)
(Continued from previous column)
Blood glucose concentration*
≤5 mmol/L 202 (20%) 207 (20%)
6–7 mmol/L 501 (49%) 485 (47%)
≥8 mmol/L 324 (32%) 347 (33%)
Treatment with antiplatelet drugs 
in previous 48 h
599 (51%) 610 (52%)
Assessment of acute ischaemic change
Scan normal 99 (8%) 102 (9%)
Scan not normal but no sign of 
acute change
551 (47%) 579 (49%)
Signs of acute change 511 (44%) 490 (42%)
Predicted probability of poor outcome at 6 months†
<40% 633 (54%) 640 (54%)
≥40–<50% 130 (11%) 113 (10%)
≥50–<75% 275 (24%) 304 (26%)
≥75% 131 (11%) 122 (10%)
Stroke syndrome
TACI 491 (42%) 509 (43%)
PACI 460 (39%) 430 (36%)
LACI 137 (12%) 133 (11%)
POCI 79 (7%) 104 (9%)
Other 2 (<1%) 3 (<1%)
Data are n (%). TACI=total anterior circulation infarct. PACI=partial anterior 
circulation infarct. LACI=lacunar infarct. POCI=posterior circulation infarct. 
*Baseline glucose concentration was not recorded for the ﬁ rst 282 patients 
recruited; thus, glucose measurements were available for 2066 of 
2348 participants (88%; 1027 allocated to alteplase and 1039 allocated to 
control). †Calculated from a model based on age and baseline National Institutes 
of Health stroke scale score.22 
Table 1: Baseline characteristics of patients included in 18-month 
follow-up 
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We also assessed binary (yes or no) answers to two 
questions, about global functioning: ”Has the stroke left 
you with any problems?” and activities of daily living: “Do 
you need help from anybody with everyday activities (in 
washing, dressing, feeding, and going to the toilet)?” 
These questions have been validated17 and were used 
previously in a large trial.20 We also asked whether patients 
were living in their own home, a relative’s home, a 
residential home, a nursing home, or were still in hospital. 
Finally, the questionnaire asked patients enrolled in the 
open-label treatment phase what treatments they recalled 
being given in hospital, including thrombolysis with 
alteplase. If the patient or proxy did not complete a speciﬁ c 
item on a postal questionnaire, we did not re-contact 
them. 
Statistical analysis
All randomly assigned patients who were due to be 
followed up at 18 months were included in the analysis of 
survival. We constructed Kaplan-Meier survival curves, 
and compared treatment groups with the log-rank test. 
Survival times were censored at 548 days after enrolment 
if patients died at a later date or returned an 18-month 
form at a later date. For patients from the Australia, 
Norway, Sweden, and UK, where reporting of deaths was 
prompt, if there was no known death date and no return 
of an 18-month form, patients were censored at 548 days. 
For patients from other countries who had no reported 
death date and no 18-month form, survival was censored 
at the date of return of the 6-month form or at the last 
date of contact, whichever was later. The justiﬁ cation for, 
and the methods for statistical adjustment of, the 
outcomes and the ordinal analyses of the Oxford 
handicap scale score at 18 months were speciﬁ ed in the 
statistical analysis plan and also described in the report 
of the primary outcomes.2,5 We divided the Oxford 
handicap scale into ﬁ ve levels: 0, 1, 2, and 3 were retained 
and 4, 5, and 6 were combined into a single level. The 
treatment OR between one level and the next was 
assumed to be constant, so a single parameter (a 
common OR) summarises the shift in outcome 
distribution between treatment and control groups. 
In the main analysis, we report results without imputing 
missing data. In the sensitivity analysis, for patients with 
an unknown Oxford handicap scale score at 18 months, we 
imputed the value from their 6-month assessment (last 
observation carried forward). For the EuroQoL instrument, 
we analysed the three levels of each EQ-5D domain as 
ordered categories by ordinal logistic regression, calculated 
the mean overall diﬀ erence in visual analogue scale score 
between treatment groups, and estimated the EQ-5D 
index—calculated with a set of valuations derived from a 
sample of the UK population with the time trade-oﬀ 
method and also the UK visual analogue scale and 
European visual analogue scale valuations.12 Analyses were 
adjusted for baseline prognostic factors (age, National 
Institutes of Health stroke scale score, delay between onset 
and enrolment, and presence of acute ischaemic change 
on the baseline scan). We did several sensitivity analyses to 
assess the eﬀ ect of missing data for Oxford handicap scale 
score and EQ-5D, and we assessed the eﬀ ect of setting 
utility to zero for patients who had died. We did subgroup 
analyses of the eﬀ ect of treatment on Oxford handicap 
scale score (ordinal logistic regression, as in the study by 
Frank and colleagues21) and utility subdivided by age 
(>80 vs ≤80 years), time to randomisation (≤3·0, >3·0–4·5, 
>4·5–6·0 h), baseline National Institutes of Health stroke 
scale score (0–5, 6–15, 16–25, >25), phase of the trial 
(masked vs open label), and by the person completing the 
form (patient vs proxy). For National Institutes of Health 
stroke scale score, we also ﬁ tted a model with baseline 
severity as a linear regressor with treatment-speciﬁ c 
slopes. Analyses were done with SAS (version 9.3). 
This study is registered with controlled-trials.com, 
number ISRCTN25765518.
Role of the funding source
The sponsors had no role in data collection, data storage, 
data analysis, preparation of this report, or the decision 
to publish. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
Of the 3035 patients enrolled by 156 hospitals in 
12 countries, 2348 (77·4%) met the criteria for inclusion in 
the 18-month follow-up study—1169 assigned to alteplase, 
1179 assigned to control (ﬁ gure 1). The baseline 
characteristics of this subset were well balanced between 
groups (table 1) and were not much diﬀ erent from those 
who were ineligible for the 18-month follow-up analysis 
(appendix). 
Of the 2348 patients scheduled for 18-month follow-up, 
vital status and Oxford handicap scale score at 18 months 
were known for 2290 (97·5%). Survival at 18 months did 
Figure 2: Kaplan-Meier survival curves
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not diﬀ er signiﬁ cantly between groups: 408 of 1169 
(34·9%) participants allocated to alteplase versus 
414 of 1179 (35·1%) allocated to control died (log-rank 
p=0·85; ﬁ gure 2). 
At 18 months, of 2348  participants, vital status and 
disability were known for 2239 (95·3 %), vital status only 
was known for 51 (2·2%), and vital status and disability 
were unknown for 58 (2·5%). Oxford handicap scale 
scores were available for 1117 participants assigned to 
alteplase versus 1122 assigned to control. 391 (35·0%) 
patients allocated to alteplase versus 352 (31·4%) 
allocated to control were alive and independent (Oxford 
handicap scale score 0–2) at 18 months (adjusted 
odds ratio 1·28, 95% CI 1·03–1·57; p=0·024; unadjusted 
OR 1·18, 95% CI 0·99–1·40; p=0·068; table 2), with a 
favourable shift in Oxford handicap scale score (adjusted 
common OR 1·30, 95% CI 1·10–1·55; p=0·002). The size 
and statistical signiﬁ cance of the eﬀ ect on Oxford 
handicap scale score at 18 months was robust to 
sensitivity analyses for missing data (data not shown). 
The appendix shows Oxford handicap scale score at 
6 months in patients scheduled for 18-month follow-up 
who had data available at 6 months.
The EQ utility index could be calculated for 1341 (91·3%) 
of the 1468 patients who were alive at 18 months. 591 
(44%) of these assessments were completed by patients 
themselves, 724 (54%) by a valid proxy, and 25 (2%) by a 
doctor. Treatment was associated with signiﬁ cant 
improvements in mobility, self-care, ability to do usual 
activities, and pain or discomfort, with no evidence of an 
eﬀ ect on anxiety or depression (table 3). At 18 months, 
alteplase was associated with signiﬁ cantly fewer patients 
reporting being left with problems and needing help 
with everyday activities (table 3).
Although treatment with alteplase was associated with 
a signiﬁ cantly higher EQ utility index in survivors 
(p=0·028; table 4), the mean adjusted diﬀ erence in visual 
analogue scale score was not signiﬁ cant (p=0·072; 
table 4). These ﬁ ndings were robust in the sensitivity 
analyses (data not shown). The appendix shows EQ-5D, 
EQ utility index, and visual analogue scale score at 
6 months and 18 months using diﬀ erent valuations. Of 
the participants who were still alive, the proportion who 
were resident at home did not diﬀ er signiﬁ cantly between 
groups (appendix).
For the ordinal subgroup analysis of Oxford handicap 
scale score at 18 months, signiﬁ cant interactions existed 
between baseline variables and treatment eﬀ ect. Greater 
diﬀ erences in favour of alteplase were reported for age 
older than 80 years (p=0·032) and high National 
Institutes of Health stroke scale score (p=0·021), but not 
for time to treatment, respondent (patient vs proxy), or 
masking of assessment of outcome (double blind vs 
open label; appendix). When age, delay, and National 
Institutes of Health stroke scale score were treated as 
continuous variables, the interaction of ordinal Oxford 
handicap scale score with age became non-signiﬁ cant, 
delay remained non-signiﬁ cant, and for National 
Institutes of Health stroke scale score the p value for a 
trend was 0·004 (appendix). For EQ utility index, when 
Alteplase 
group
Control 
group
Adjusted anaylsis* Unadjusted analysis† Diﬀ erence per 
1000 patients† 
(95% CI)
OR (95% CI) p 
value
OR (95% CI) p 
value
Planned 18-month follow-up 1169 1179 ·· ·· ·· ·· ··
Missing OHS data at 18 months‡ 52 (4%) 57 (5%) ·· ·· ·· ·· ··
Number analysed (both vital and OHS status 
known) 
1117 (96%) 1122 (95%) ·· ·· ·· ·· ··
OHS score at 18 months§
0 119 (11%) 83 (7%) ·· ·· ·· ·· ··
1 135 (12%) 141 (13%) ·· ·· ·· ·· ··
2 137 (12%) 128 (11%) ·· ·· ·· ·· ··
3 132 (12%) 138 (12%) ·· ·· ·· ·· ··
4 81 (7%) 107 (10%) ·· ·· ·· ·· ··
5 105 (9%) 111 (10%) ·· ·· ·· ·· ··
Died before 18 months§¶ 408 (37%) 414 (37%) 0·95 (0·78 to 1·16) 0·628 0·98 (0·83 to 1·17) 0·855 4 (–36 to 44)
Alive and independent (OHS score 0–2)§ 391 (35%) 352 (31%) 1·28 (1·03 to 1·57) 0·024 1·18 (0·99 to 1·40) 0·068 –36 (–75 to 3)
Alive and had favourable outcome 
(OHS score 0 or 1)§
254 (23%) 224 (20%) 1·23 (0·98 to 1·55) 0·076 1·18 (0·96 to 1·44) 0·109 –28 (–62 to 6)
Data are n (%) unless stated otherwise. OHS=Oxford handicap score. *Logistic regression of outcome on treatment group, adjusted for age, National Institutes of Health 
stroke scale score, and delay (all linear) and visible infarct on baseline scan. †Standard binomial test with normal approximation. ‡Includes patients who did not return an 
18-month form but died more than 18 months after enrolment (ﬁ gure 1). §Percentages based on number analysed for OHS. For one participant, OHS was imputed on the 
basis of responses to EQ-5D. ¶If all patients known to be alive are included in the denominators, the percentage dead at 18 months are 35·8% in the alteplase group and 
36·0% in the control group. 
Table 2: Oxford handicap scale scores at 18 months
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subgroups were in discrete categories, none of the 
interactions were statistically signiﬁ cant (appendix). 
However, when the National Institutes of Health stroke 
scale score was treated as continuous, every ﬁ ve-point 
increase in score reduced the EQ utility index by 
0·12 in the alteplase group versus 0·15 in the control 
group (adjusted estimates; p=0·008 for diﬀ erence in 
slopes). For delay in enrolment time and age there was 
no trend in EQ utility index, irrespective of whether the 
variables were grouped or entered into models as a 
linear trend (data not shown).
Of the 1468 patients who were alive at 18 months, 1260 
were asked to recall if they had been given thrombolytic 
treatment (appendix); 273 in the alteplase group versus 
156 in the control group correctly recalled whether or not 
they had received thrombolytic treatment. In both 
treatment groups, the ability to recall treatment correctly 
was associated with better outcome; patients with correct 
recall were more likely to have an Oxford handicap scale 
score of 0–2 than were those who remembered incorrectly 
or did not know (62·5% vs 49·3%; 0·0001). Of patients 
with correct recall, those treated with alteplase were more 
likely to have an Oxford handicap scale score of 0–2 than 
were those in the control group (66·7% vs 55·1%; 0·018), 
whereas of those who did not remember correctly, 
outcomes did not diﬀ er signiﬁ cantly between groups 
(OHS 0–2 48·6% vs 49·9%; 0·714); a signiﬁ cant interaction 
existed between recall status and treatment (p<0·0001).
Alteplase 
group
Control 
group 
Odds ratio (95% CI)* p value Diﬀ erence per 1000 
patients† (95% CI)
EQ-5D
Mobility 702 692 ·· ·· ··
No problems walking 283 (40%) 259 (37%) 1·30 (1·05 to 1·61) 0·017 –29 (–80 to 22)
Some problems walking 343 (49%) 346 (50%) ·· ·· 11 (–41 to 64)
Conﬁ ned to bed 76 (11%) 87 (13%) ·· ·· 17 (–16 to 51)
Self-care 695 689 ·· ·· ··
No problems with self-care 372 (54%) 328 (48%) 1·43 (1·16 to 1·78) 0·001 –59 (–112 to –7)
Some problems washing or dressing 176 (25%) 191 (28%) ·· ·· 24 (–23 to 70)
Unable to wash or dress 147 (21%) 170 (25%) ·· ·· 35 (–9 to 79)
Usual activities 699 694 ·· ·· ··
No problems with usual activities 235 (34%) 209 (30%) 1·32 (1·07 to 1·62) 0·008 –35 (–84 to 14)
Some problems with usual activities 258 (37%) 256 (37%) ·· ·· 0 (–51 to 50)
Unable to do usual activities 206 (29%) 229 (33%) ·· ·· 35 (–13 to 84)
Pain or discomfort 698 694 ·· ·· ··
No pain or discomfort 344 (49%) 304 (44%) 1·26 (1·02 to 1·56) 0·029 –55 (–107 to –2)
Moderate pain or discomfort 316 (45%) 355 (51%) ·· ·· 59 (6 to 111)
Extreme pain or discomfort 38 (5%) 35 (5%) ·· ·· –4 (–27 to 19)
Anxiety or depression 693 690 ·· ·· ··
Not anxious or depressed 353 (51%) 349 (51%) 1·05 (0·85 to 1·29) 0·668 –4 (–56 to 49)
Moderately anxious or depressed 292 (42%) 290 (42%) ·· ·· –1 (–53 to 51)
Extremely anxious or depressed 48 (7%) 51 (7%) ·· ·· 5 (–23 to 32)
Additional questions about overall function
Stroke left patient with problems 484/700 (69%) 542/699 (78%) 1·67 (1·30 to 2·17) <0·0001 84 (38 to 130)
Needs help with everyday activities 298/696 (43%) 350/692 (51%) 1·59 (1·25 to 2·00) <0·0001 78 (25 to 130)
Data are n (%) unless stated otherwise.*Logistic regression of outcome on treatment group, adjusted for age, National Institutes of Health stroke scale score, and delay (all 
linear) and visible infarct on baseline scan. †Standard binomial test with normal approximation. 
Table 3: EQ-5D and other assessments of function at 18 months
Alteplase group Control group Adjusted analysis* Unadjusted analysis†
n Mean (SE) n Mean (SE) Mean diﬀ erence (SE) p 
value
Mean diﬀ erence (SE) p value
Visual analogue scale score 653 62·07 (0·90) 648 60·57 (0·91) 2·18 (1·21) 0·072 1·49 (1·28) 0·244
EQ utility index 674 0·550 (0·015) 667 0·502 (0·016) 0·062 (0·020) 0·002 0·049 (0·022) 0·028
*Adjusted for age, National Institutes of Health Stroke Scale score, delay from onset to enrolment, and presence of visible ischaemia on the baseline scan. †Signiﬁ cance based 
on t test. Utility based on UK time trade-oﬀ  valuations on a scale of –1 to +1.
Table 4: EQ utility index and visual analogue scale score assessment of overall health at 18 months
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Discussion
We have shown that, for treatment of acute ischaemic 
stroke, thrombolysis with intravenous alteplase seems to 
provide a beneﬁ t at 18 months. Treatment had no eﬀ ect 
on survival, but was associated with a signiﬁ cant increase 
in the likelihood of being alive and independent. 
However, the unadjusted absolute diﬀ erence in the 
number of patients alive and independent at 18 months 
was not signiﬁ cant, so judgment on whether or not the 
results are clinically signiﬁ cant rests on the quality of the 
data and the overall patterns of eﬀ ect seen across all 
measures. The ordinal estimates of eﬀ ect at 6 months 
and 18 months were similar and signiﬁ cant. Treatment 
was also associated with a gain in health-related quality 
of life that was signiﬁ cant for four of the ﬁ ve dimensions 
of the EQ-5D and the overall EQ utility index (though not 
for visual analogue scale score). Living circumstances did 
not diﬀ er signiﬁ cantly between groups. 
Strengths of this study are the large number of patients 
and the completeness of follow-up. Of the patients 
scheduled for 18-month follow-up, a small proportion were 
missing data for both vital and functional outcome status. 
We estimated the EQ utility index in more than 91% of 
survivors (a similar proportion to that in a trial23 of younger 
and less impaired patients with coronary artery disease) 
and our sensitivity analyses also showed that the estimates 
of overall health-related quality of life with the EQ utility 
index were robust to various assumptions about missing 
data. Although thrombolytic treatment was associated in 
survivors with less functional impairment, better 
health-related quality of life, and less likelihood of being 
left with problems and needing help with daily activities 
after stroke, it did not translate into a higher proportion of 
patients living at home at 18 months, perhaps because 
living circumstances are aﬀ ected by social and ﬁ nancial 
factors that are not inﬂ uenced by treatment. We believe 
that the direction and size of the eﬀ ects are clinically 
signiﬁ cant and will inform health economic assessments 
of thrombolytic treatment. For example, in 2002, the 
estimated cost of long-term care of an independent 
survivor of stroke was £876 per year and that of a dependent 
survivor was £11 292 per year,24 so even a small diﬀ erence 
in the proportion of patients who survive and are 
independent will have substantial economic impact. 
Lyden25 has identiﬁ ed limitations of IST-3, chieﬂ y that 
treatment was not masked. Patient-reported outcomes—
eg, health-related quality of life—are subjective,26 and recall 
of thrombolytic treatment could aﬀ ect patient responses. 
Only 30% of survivors correctly recalled whether or not 
they had received thrombolytic treatment. As expected, 
accurate recall was associated with better outcome in both 
treatment groups. Thus, recall bias might have aﬀ ected 
our ﬁ ndings. However, the analysis of recall was based on 
a variable measured in a subset of survivors after 
randomisation and so could itself be biased. The eﬀ ects of 
treatment on the Oxford handicap scale score and EQ 
utility index were much the same in the masked and 
open-label parts of the study (appendix). Assessment of 
health-related quality of life is limited because many 
patients who have had a stroke are unable to complete the 
form themselves. The high proportion of forms completed 
by a proxy in IST-3 is a result of the severity of stroke in the 
patients included in the trial. Although the use of 
surrogates is a potential weakness, it did enable us to 
achieve satisfactory response rates; however, because 
proxies tend to assign worse health status than do 
patients,15 we were reassured that there was no interaction 
between the person responding and the eﬀ ect of treatment 
on utility or Oxford handicap scale score. Not all enrolled 
patients were scheduled to be followed up for 18 months, 
but the selection criteria for the longer follow-up cohort 
did not seem to introduce relevant imbalances at baseline, 
nor were the characteristics of the cohort substantially 
diﬀ erent from those not included in long-term follow-up. 
We therefore believe the 18-month follow-up cohort is 
representative of the trial as a whole. 
Another weakness is that the trial was under-powered, so 
the subgroup analyses of the eﬀ ects of baseline age, stroke 
severity, and delay to enrolment on the Oxford handicap 
Panel: Research in context 
Systematic review
The primary results of IST-32 included a systematic review of randomised controlled trials 
of alteplase in acute stroke.1 To accompany this review we searched up to April 30, 2013, 
for additional randomised trials of intravenous alteplase versus control within 6 h of 
onset of acute stroke in the Cochrane Stroke Trials Registry, Internet Stroke Trials Centre, 
and reference lists in review articles and conference abstracts. For the Cochrane Stroke 
Trials Registry we searched for interventions with thrombolytic drugs in acute ischaemic 
stroke added since the last update of the Cochrane review. For the Internet Stroke Center, 
we searched for “acute ischemic stroke”, “acute ischaemic stroke”, “thrombolysis”, 
“thrombolytic therapy”, “alteplase”, and “recombinant tissue plasminogen activator”. For 
each trial, we checked the primary trial publication, and when available, the trial protocol, 
to determine if it was planned to collect long-term clinical outcome data (ie, more than 
90 days after enrolment) or health-related quality-of-life data, as assessed by a valid 
instrument such as EQ-5D or Short Form 36.
Of the 12 completed randomised controlled trials, ten reported outcome at 90 days or 
less,1 two reported clinical outcome at 6 months2,3 and one at 12 months,3 but none 
reported eﬀ ects more than 12 months after stroke. The Second European Collaborative 
Acute Stroke Study collected data on health-related quality of life at 90 days with the 
SF-36, but has yet to report those data. In the NINDS Trial,3 mortality at 12 months did not 
diﬀ er signiﬁ cantly between alteplase and placebo groups (24% vs 28%; p=0·29). The primary 
outcome was favourable outcome, deﬁ ned as minimal or no disability as measured by the 
Barthel index, the modiﬁ ed Rankin scale, and the Glasgow outcome scale, and the treatment 
eﬀ ect was assessed with a global statistic. The global statistic favoured the alteplase group at 
6 months (OR for a favourable outcome 1·7, 95% CI 1·3–2·3) and at 12 months (1·7, 1·2–2·3). 
Interpretation
IST-3 conﬁ rms the evidence from previous trials on the neutral eﬀ ect of thrombolysis with 
alteplase on survival after stroke in a much larger sample, and adds to the evidence that 
improvements in function reported at earlier timepoints are evident at 18 months. IST-3 
also provides the ﬁ rst validated estimates of the eﬀ ect of thrombolysis with alteplase on 
health-related quality of life.
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scale score and health-related quality of life should be 
treated with caution. These are secondary analyses of a 
secondary outcome, and the apparent lack of eﬀ ect of time 
to treatment might be due to chance. Furthermore, a more 
appropriate assessment of the complex interactions 
between age, stroke severity, and time to treatment will be 
available from a meta-analysis of individual patient data by 
the Stroke Thrombolysis Trialists.27
In conclusion, IST-3 adds to the evidence from previous 
trials (panel) and shows that although thrombolysis for 
acute ischaemic stroke with intravenous alteplase does 
not improve survival, there is evidence of improvement 
in several measures of function and quality of life in 
survivors of all ages for up to 18 months after treatment. 
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